Eli Lilly & Co. (LLY): Price and Financial Metrics

Eli Lilly & Co. (LLY): $317.59

-5.41 (-1.67%)

POWR Rating

Component Grades














  • Quality is the dimension where LLY ranks best; there it ranks ahead of 92.4% of US stocks.
  • LLY's strongest trending metric is Value; it's been moving down over the last 179 days.
  • LLY ranks lowest in Momentum; there it ranks in the 8th percentile.

LLY Stock Summary

  • With a market capitalization of $274,647,387,667, ELI LILLY & Co has a greater market value than 99.41% of US stocks.
  • ELI LILLY & Co's stock had its IPO on January 1, 1986, making it an older stock than 92.84% of US equities in our set.
  • Price to trailing twelve month operating cash flow for LLY is currently 37.83, higher than 85.92% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ELI LILLY & Co are PFE, ABBV, MRK, NVO, and NVS.
  • Visit LLY's SEC page to see the company's official filings. To visit the company's web site, go to www.lilly.com.

LLY Valuation Summary

  • LLY's price/earnings ratio is 40.7; this is 11.51% higher than that of the median Healthcare stock.
  • Over the past 243 months, LLY's price/earnings ratio has gone up 13.
  • LLY's price/earnings ratio has moved up 13 over the prior 243 months.

Below are key valuation metrics over time for LLY.

Stock Date P/S P/B P/E EV/EBIT
LLY 2021-08-31 9.2 38.3 40.7 37.3
LLY 2021-08-30 9.4 38.9 41.3 37.9
LLY 2021-08-27 9.3 38.6 40.9 37.5
LLY 2021-08-26 9.4 38.8 41.2 37.7
LLY 2021-08-25 9.4 39.2 41.6 38.1
LLY 2021-08-24 9.4 39.0 41.4 37.9

LLY Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 10.11%.
  • Its 4 year net cashflow from operations growth rate is now at 93.93%.
  • Its 3 year revenue growth rate is now at 18.68%.
Over the past 34 months, LLY's revenue has gone up $4,370,500,000.

The table below shows LLY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 28,318.4 7,260.7 5,581.7
2021-09-30 27,758.5 6,919.4 5,972.4
2021-06-30 26,726.3 7,094.7 6,070.7
2021-03-31 25,485.6 7,814.6 6,092.5
2020-12-31 24,539.8 6,499.6 6,193.7
2020-09-30 23,213.8 6,648.1 5,572.6

LLY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LLY has a Quality Grade of B, ranking ahead of 90.11% of graded US stocks.
  • LLY's asset turnover comes in at 0.586 -- ranking 60th of 681 Pharmaceutical Products stocks.
  • BHC, VRTX, and DRRX are the stocks whose asset turnover ratios are most correlated with LLY.

The table below shows LLY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.586 0.748 0.191
2021-06-30 0.577 0.743 0.199
2021-03-31 0.568 0.759 0.203
2020-12-31 0.565 0.777 0.214
2020-09-30 0.558 0.783 0.198
2020-06-30 0.573 0.787 0.202

LLY Price Target

For more insight on analysts targets of LLY, see our LLY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $265.88 Average Broker Recommendation 1.5 (Moderate Buy)

LLY Stock Price Chart Interactive Chart >

Price chart for LLY

LLY Price/Volume Stats

Current price $317.59 52-week high $330.85
Prev. close $323.00 52-week low $220.20
Day low $317.59 Volume 1,222
Day high $317.59 Avg. volume 2,997,611
50-day MA $299.68 Dividend yield 1.21%
200-day MA $267.71 Market Cap 301.76B

Eli Lilly & Co. (LLY) Company Bio

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. (Source:Wikipedia)

LLY Latest News Stream

Event/Time News Detail
Loading, please wait...

LLY Latest Social Stream

Loading social stream, please wait...

View Full LLY Social Stream

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.

Eli Lilly Stock Shows Improved Relative Strength Performance With 84 RS Rating

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance.

Investor''s Business Daily | February 25, 2022

Friday, Feb. 25, 2022: Jim Cramer on selling some Chevron for growth stock buying opportunities

Jim Cramer and Jeff Marks break down recent market movements reflecting Russia-Ukraine developments. They explain why they sold some Chevron shares and bought growth stocks including Qualcomm, Morgan Stanley, Eli Lilly, Wells Fargo, and Bausch Health. They also take a deep dive into why they''re watching PayPal, Google, and Linde.

CNBC | February 25, 2022

FDA Approves Jardiance To Treat Adults With Heart Failure

The U.S. Food and Drug Administration or FDA approved Boehringer Ingelheim''s diabetes drug Jardiance (empagliflozin), co developed by Eli Lilly and Co., to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance''s approval was based on its safety and effectiveness that were evaluated as an adjunct to standard of care therapy in a randomized, double-blin

RTT News | February 25, 2022

Androgen Replacement Therapy Market Is Booming Worldwide 2022-2028 | AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company

Coherent Market Insights published a business research report on Androgen Replacement Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022-2028. Androgen Replacement Therapy Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages

OpenPR | February 25, 2022

FDA Approves Eli Lilly''s Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE: LLY ) and partner Boehringer Ingelheim''s drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug''s use was expanded last year in some … Full story available on Benzinga.com

Benzinga | February 25, 2022

Read More 'LLY' Stories Here

LLY Price Returns

1-mo 1.32%
3-mo 8.88%
6-mo 15.85%
1-year 40.32%
3-year 197.26%
5-year 327.43%
YTD 15.85%
2021 66.08%
2020 31.04%
2019 16.14%
2018 40.45%
2017 17.83%

LLY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LLY Dividend History

Continue Researching LLY

Want to see what other sources are saying about ELI LILLY & Co's financials and stock price? Try the links below:

ELI LILLY & Co (LLY) Stock Price | Nasdaq
ELI LILLY & Co (LLY) Stock Quote, History and News - Yahoo Finance
ELI LILLY & Co (LLY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6008 seconds.